- Home
- CHGG vs DMAC Comparison
CHGG vs DMAC Comparison
Compare CHGG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHGG
- DMAC
- Stock Information
- Founded
- CHGG 2005
- DMAC 2000
- Country
- CHGG United States
- DMAC United States
- Employees
- CHGG N/A
- DMAC N/A
- Industry
- CHGG Other Consumer Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CHGG Real Estate
- DMAC Health Care
- Exchange
- CHGG Nasdaq
- DMAC Nasdaq
- Market Cap
- CHGG 149.2M
- DMAC 178.0M
- IPO Year
- CHGG 2013
- DMAC N/A
- Fundamental
- Price
- CHGG $1.29
- DMAC $3.63
- Analyst Decision
- CHGG Sell
- DMAC Strong Buy
- Analyst Count
- CHGG 7
- DMAC 2
- Target Price
- CHGG $1.70
- DMAC $8.00
- AVG Volume (30 Days)
- CHGG 3.8M
- DMAC 325.9K
- Earning Date
- CHGG 08-04-2025
- DMAC 08-06-2025
- Dividend Yield
- CHGG N/A
- DMAC N/A
- EPS Growth
- CHGG N/A
- DMAC N/A
- EPS
- CHGG N/A
- DMAC N/A
- Revenue
- CHGG $564,611,000.00
- DMAC N/A
- Revenue This Year
- CHGG N/A
- DMAC N/A
- Revenue Next Year
- CHGG N/A
- DMAC N/A
- P/E Ratio
- CHGG N/A
- DMAC N/A
- Revenue Growth
- CHGG N/A
- DMAC N/A
- 52 Week Low
- CHGG $0.44
- DMAC $2.98
- 52 Week High
- CHGG $3.81
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CHGG 49.41
- DMAC 44.55
- Support Level
- CHGG $1.32
- DMAC $3.48
- Resistance Level
- CHGG $1.49
- DMAC $3.88
- Average True Range (ATR)
- CHGG 0.11
- DMAC 0.26
- MACD
- CHGG -0.03
- DMAC 0.00
- Stochastic Oscillator
- CHGG 41.43
- DMAC 30.10
About CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.